Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • Pazdur declines to announce candidacy for vacated FDA commissioner role
  • Regulatory

Pazdur declines to announce candidacy for vacated FDA commissioner role

BioSpace

FDA veteran Richard Pazdur outlined his priorities for the next FDA commissioner but stopped short of putting himself forward as a candidate to lead the agency at an RBC Capital Markets event on Tuesd

Read full story

pharminent May 20, 2026 (Last updated: May 20, 2026)

BioSpace

FDA veteran Richard Pazdur outlined his priorities for the next FDA commissioner but stopped short of putting himself forward as a candidate to lead the agency at an RBC Capital Markets event on Tuesd

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Pepaxti study supports use in wider myeloma population
Next: Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Related Stories

  • Regulatory

Outlook Therapeutics Secures FDA Approval for LYTENAVA

pharminent July 31, 2026
  • Regulatory

Outlook finally claims FDA approval for AMD drug

pharminent July 27, 2026
  • Regulatory

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

pharminent July 27, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.